Transaction #32830 · Form 4 · 0000907654-26-000106
Oruka Therapeutics, Inc. · Exercise / conversion · Common Stock
Oruka Therapeutics, Inc. · Transacted October 12, 2026 · Filed October 13, 2026
What does this filing report?
An SEC Form 4 filing for Oruka Therapeutics, Inc. records an exercise / conversion involving Common Stock on October 12, 2026. The reported quantity was 1,458. The filing date is October 13, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Oruka Therapeutics, Inc.
- Company CIK
- 0000907654
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 1,458
- Reported price
- 34.39
- Reference value
- 50,140.62
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 24,218
- Ownership description
- Not reported
- SEC acceptance time
- Oct 13, 2026, 4:34 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Agarwal Arjun ↗
Senior Vice President, Finance
CIK 0002033974
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
- F2
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.55 to $80.54, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
- F3
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.56 to $81.53, inclusive.
- F4
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.61 to $82.50, inclusive.
- F5
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.76 to $82.91, inclusive.
- F6
- The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
- F7
- The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.